PolyPid Announces Issuance Of New U.S. Patent For Doxycycline Sustained Release Compositions

PolyPid, a clinical stage pharmaceutical company and developer of PLEX, a protected drug reservoir platform for effective localized, controlled and prolonged drug delivery, recently announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 9,173,976, covering compositions for sustained and/or controlled release of doxycycline. Specifically, the patent, which expires in 2033, covers matrix compositions comprising PLGA, cholesterol, a mixture of DPPC and DSPC, and doxycycline hyclate. In addition, U.S. Patent No. 9,173,976 contains claims related to bone filler particles coated with said matrix compositions and their use in the treatment of open bone fractures.

This newly issued patent further enhances the company's patent portfolio covering PolyPid's PLEX delivery platform, which includes U.S. Patent Nos. 8,877,242, 8,992,979 and 8,795,726, in addition to 8 granted patents in Japan, China, Hong-Kong and Israel and over 50 patent applications in different stages of prosecution.

“The patent is an important milestone for PolyPid’s strategy and it advances our portfolio further towards commercialization. It strengthens our overall PLEX platform patent protection, and specifically protects our leading product candidate, BonyPid-1000, a doxycycline hyclate loaded bone substitute, and its use in the treatment of contaminated bone fractures, eventually offering an improvement over the common systemic treatment which is of limited efficacy in such cases,” said Dr. Noam Emanuel, PolyPid’s Chief Technology Officer.

Earlier this year, PolyPid received approval from European regulatory authorities to commence a multicenter clinical study to explore the utility of its leading product candidate, BonyPid-1000, in 64 patients with open contaminated fractures. The planned study is expected to commence by the end of 2015 in various medical centers in Israel and the Philippines.

About PolyPid
PolyPid is a clinical stage, emerging specialty pharmaceutical company developing, manufacturing and eventually commercializing products based on a proprietary platform named PLEX (Polymer-Lipid Encapsulation matriX) in the field of extended release, local drug delivery. PLEX-based protected drug reservoirs enable prolonged delivery of sensitive drugs over periods ranging from days to several months. The application of PLEX technology enables optimizing drug treatment regimens by predetermining release rates and durations, a rare combination of attributes.

PolyPid’s lead product, BonyPid-1000, comprises antibiotic eluting ß tri-calcium phosphate (ßTCP) granules, intended to fill bone voids while protecting against infections. For more information, visit www.polypid.com.